Abstract Sandhoff disease (SD) is a glycosphingolipid (GSL) storage disease that arises from an autosomal recessive mutation in the gene for the b-subunit of bHexosaminidase A (Hexb gene), which catabolizes ganglioside GM2 within lysosomes. Accumulation of GM2 and asialo-GM2 (GA2) occurs primarily in the CNS, leading to neurodegeneration and brain dysfunction. We analyzed the total lipids in the brains of SD mice, cats, and humans. GM2 and GA2 were mostly undetectable in the normal mouse, cat, and human brain. The lipid abnormalities in the SD cat brain were generally intermediate to those observed in the SD mouse and the SD human brains. GM2 comprised 38, 67, and 87% of the total brain ganglioside distribution in the SD mice, cats, and humans, respectively. The ratio of GA2-GM2 was 0.93, 0.13, and 0.27 in the SD mice, cats, and humans, respectively, suggesting that the relative storage of GA2 is greater in the SD mouse than in the SD cat or human. Finally, the myelinenriched lipids, cerebrosides and sulfatides, were significantly lower in the SD brains than in the control brains. This study is the first comparative analysis of brain lipids in mice, cats, and humans with SD and will be important for designing therapies for Sandhoff disease patients.
Introduction
Sandhoff disease (SD) is an incurable lysosomal storage disorder that arises from an autosomal recessive mutation, which causes abnormal accumulation of ganglioside GM2 leading to progressive neurodegeneration [1, 2] . GM2 is catabolized by b-hexosaminidase A (HexA), which consists of an a and a b subunit encoded by the Hexa and Hexb genes, respectively, in complex with the GM2 activator protein. GM2 accumulation can result from inherited defects in either the hexosaminidase a or b subunit, or in the GM2 activator protein, leading to Tay-Sachs disease (B variant), Sandhoff disease (O variant), or GM2 activator deficiency (AB variant), respectively. SD patients have defects in the Hexb gene, and as a result, they lack activity of both b-hexosaminidase isozymes A (ab) and B (bb). Consequently, patients accumulate GM2 and its asialo derivative, GA2, and also oligosaccharides and other hexosaminidase substrates within lysosomes [1, 2] . The onset of disease ranges from infancy to adulthood, and excessive CNS GM2 accumulation leads to progressive neurodegeneration, brain dysfunction, and ultimately death.
Although the biochemical defect in SD has been known for many years, there are presently no therapies. The development of mouse models of lysosomal storage disorders has provided the necessary tools for advancement in possible therapies and treatments. However, with some success in bone marrow transplantation, gene therapy, stem cell therapy, caloric restriction, non-steroidal anti-inflammatory drug therapy, and substrate reduction therapy in SD mice, there are still no treatments available for patients [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] .
A possible disconnect from mouse studies to clinical treatments is the difference in the applicable brain size between mouse and human. The brain weight of the mouse is around 0.4 g while an infantile human brain weighs around 400 g, representing a 1,000-fold difference in size [13] [14] [15] . A naturally occurring, authentic model of SD in cats (fG M2 Baker) has been previously characterized and could potentially serve as an intermediate model between mouse and man [16] [17] [18] [19] . Although the feline brain is closer in size and complexity to the human brain, it is not clear how the mouse and the cat animal models of SD compare to the human patient.
While the CNS GM2 accumulation has been reported for the mouse and cat models of SD and in the patient [11, [19] [20] [21] [22] , the comparative total lipid analysis has never been done. In particular, our objective was to analyze similar brain regions, at a similar phenotypic time-point, using the same methodology to compare the total lipid distribution between mice, cats, and humans with SD. Knowledge gained from this study could help provide the foundation to bridge the gap between the successes in mouse studies to treatment in patients.
Experimental Procedures

Mice
The SV/129 Hexb -/-(SD) mice were obtained from Dr. Richard Proia (NIH). These mice were derived by disruption of the murine Hexb gene and transferring this gene into the mouse genome through homologous recombination and embryonic stem cell technology as previously described [20] . Hexb -/-mice were derived from crosses of Hexb ?/-females with Hexb -/-males. Genotypes of mice were determined by measuring the specific activity of total hexosaminidase using a modification of the Galjaard procedure as previously described [23, 24] . Hexb ?/-and Hexb -/-mice were propagated in the Boston College Animal Facility and were housed in plastic cages with filter tops containing Sani-Chip bedding (P.J. Murphy Forest Products Corp., Montville, NJ, USA). Other conditions were as we recently described [12] . The cortical brain region from normal and SD mice was collected around 4 months of age (humane end-point) and stored at -80°C. All animal experiments were carried out with ethical committee approval in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care Committee.
Cats
The SD cats were obtained from the fG M2 Baker colony and have been previously described [17, 19] . Sequence analysis determined that the causative mutation in this domestic shorthair SD cat resulted from a 25-base-pair inversion at the 3 0 end of the Hexb gene [16] . Affected cats have \3% normal hexosaminidase activity in cerebral cortex and, therefore, represent an authentic model to study Sandhoff disease. Animals were euthanized by pentobarbital overdose according to recommendations of the AVMA Panel on Euthanasia, then transcardially perfused with heparinized, cold saline (0.9% NaCl) until jugular perfusate was clear. Cerebral cortex samples were collected from normal and SD cats around 5 months of age (humane end-point) and were frozen immediately in liquid nitrogen and stored at -80°C until use. All animal procedures were approved by the Auburn University Institutional Animal Care and Use Committee.
Human Samples
Age-matched normal and SD human cortex samples were obtained from the NICHD Brain and Tissue Bank for Developmental Disorders at the University of Maryland, Baltimore.
Lipid Isolation, Purification, and Quantitation
Total Lipid Extraction
The lipids were isolated from frontal lobe regions of the SD patients and the cats, and from the entire cortex of the SD mice. Total lipids were extracted with chloroform (CHCl 3 ) and methanol (MeOH) 1:1 by volume and purified from the lyophilized brain tissue using modifications of previously described procedures [12, 25, 26] .
Column Chromatography
Neutral and acidic lipids were separated using DEAESephadex (A-25, Pharmacia Biotech, Upsala, Sweden) column chromatography as previously described [27] . The total lipid extract, suspended in CHCl 3 :CH 3 OH:dH 2 0, 30:60:8 by volume (solvent A), was applied to a DEAESephadex column (1.2 mL bed volume) that had been equilibrated prior with solvent A. The column was washed twice with 20 mL solvent A and the entire neutral lipid fraction, consisting of the initial eluent plus washes, was collected. This fraction contained cholesterol, phosphatidylcholine, phosphatidylethanolamine and plasmalogens, sphingomyelin, and neutral GSLs to include cerebrosides and asialo-GM2 (GA2). Next, acidic lipids were eluted from the column with 35 mL CHCl 3 :CH 3 OH:0.8 M Na acetate, 30:60:8 by volume.
Ganglioside Purification
The acidic lipid fraction containing gangliosides was dried by rotary evaporation and then partitioned to separate the acidic lipids into the lower organic phase and the gangliosides into the upper aqueous phase as previously described [25, 28, 29] . The amount of sialic acid in the ganglioside fraction was determined by the resorcinol assay and then the ganglioside fraction was further purified with base treatment and desalting, as previously described [24, 26] .
Acidic Phospholipid Purification
After the ganglioside fraction (Folch upper phase) was transferred, the acidic phospholipid fraction (Folch lower phase) was evaporated under a stream of nitrogen and resuspended in 10 mL of CHCl 3 :CH 3 OH (1:1 by volume). This fraction contained fatty acids, cardiolipin, phosphatidylserine, phosphatidylinositol, and sulfatides.
Neutral Lipid Purification
Neutral lipids were dried by rotary evaporation and resuspended in 10 mL CHCl 3 :CH 3 OH (2:1 by volume). To further purify GA2, a 4 mL aliquot of the neutral lipid fraction was evaporated under a stream of nitrogen, base treated with 1 N NaOH, and Folch partitioned as described previously [26] . The Folch lower phase containing GA2 was evaporated under a stream of nitrogen and re-suspended in 5 mL CHCl 3 :CH 3 OH (2:1 by volume).
High-Performance Thin-Layer Chromatography
All lipids were analyzed qualitatively by high-performance thin-layer chromatography (HPTLC) according to previously described methods [25] [26] [27] 30] . To enhance precision, an internal standard (oleoyl alcohol) was added to the neutral and acidic lipid standards and samples as previously described [27] . Purified lipid standards were either purchased from Matreya Inc. (Pleasant Gap, PA, USA), Sigma (St Louis, MO, USA), or were a gift from Dr. Robert Yu (Medical College of Georgia, Augusta, GA, USA).
For gangliosides and GA2, the HPTLC plates were developed and visualized as previously described [26] . For neutral and acidic phospholipids, the plates were developed to a height of either 4.5 or 6 cm, respectively, with chloroform:methanol:acetic acid:formic acid:water (35:15: 6:2:1 by volume), and then both were developed to the top with hexanes:diisopropyl ether:acetic acid (65:35:2 by volume) as previously described [27, 31] . Neutral and acidic phospholipids were visualized by charring with 3% cupric acetate in 8% phosphoric acid solution, followed by heating in an oven at 165°C for 7 min. The percentage distribution and density of individual bands was determined as previously described [26] . Briefly, the HPTLC plates were scanned on a personal Densitometer SI with ImageQuant software (Molecular Dynamics) or on a ScanMaker 4800 with ScanWizard5 V 7.00 software (Microtek). The total brain ganglioside distribution was normalized to 100% and the percentage distribution values were used to calculate sialic acid concentration of individual gangliosides as we previously described [32] . The density value for GA2 was fit to a standard curve of known lipid concentration and used to calculate concentration. For the neutral and the acidic phospholipids, each lipid was normalized to an internal standard (oleyl alcohol) and its concentration was quantified using a standard curve of each respective lipid.
Statistical Analysis
All data were analyzed by the two-tailed Student's t test to calculate statistical significance between the normal and the SD samples using Statview 5.0 software.
Results
Our objective was to compare the lipid distribution in the cerebral cortex of mice, cats, and humans with Sandhoff disease, using our established lipid isolation procedures. The comparative lipid analysis, to include gangliosides and neutral and acidic phospholipids, was done in age-matched normal and SD mice and cats at their respective humane end-points. Although the samples were not collected at ''identical'' time points in disease progression, they were collected at ''similar'' time points. Since the SD human samples were collected during autopsy from diseased patients, we elected to collect tissue from the SD mice and cats at a humane end-point to correlate our analysis with the human samples. The humane end point used for the mice was about 120 days [11] . The SD cat samples were collected from mid to terminal disease stage under the guidance of Auburn University's Institutional Animal Care and Use Committee. Disease progression in SD cats is stereotypical and is charted primarily by neuromuscular function. Disease onset begins at about 8 weeks with a slight head tremor, and the animal progressively loses ability to ambulate. Mid-disease is reached at about 12 weeks, when the animal has an unstable gait and falls occasionally. The humane endpoint occurs at approximately 20 weeks, when the animal can no longer walk or sit upright. Our study is the first to compare the total lipid distribution at a similar point in disease progression in mice, cats, and humans with Sandhoff disease.
The Hexb mutations in the mice and cats studied in this report generate similar levels of residual total hexosaminidase activity in brain, about 3% of normal levels in both models [9, 10, 19, 20] . While the mouse mutation is a targeted disruption of the Hexb gene after the 12th of 14 exons, the cat mutation results in a premature termination codon in exon 14. While we are uncertain whether the artificial 4MUG substrate used for enzyme assays reflects the true enzymatic activity toward native gangliosides, we consider that the mouse and cat mutations are functionally equivalent. Consequently, differences in ganglioside storage profiles are more likely due to inter-species differences in ganglioside metabolism than to differences in residual enzyme activity.
Gangliosides
The total brain ganglioside concentration in mice, cats, and humans is shown in Table 1 . In general, the total brain ganglioside concentrations in the normal animals are relatively similar among species. While all of the SD brains have significantly elevated total brain ganglioside concentrations compared to normal, the percent increase in total brain ganglioside concentration was greatest in the SD human (337%), followed by the SD cat (262%), and then the SD mouse (162%). The quantitative and qualitative distribution of individual gangliosides in the mice, cats, and human with SD is shown in Fig. 1 and in Table 2 . The most significant finding was that GM2 comprised 38, 67, and 87% of the total brain ganglioside distribution in the SD mice, cats, and human, respectively. While the percent distribution for GM1, GD1a, GT1a/LD1, GD1b, GT1b, and GQ1b in the SD mouse and the SD cat were significantly different than that of normal, these differences were not associated with significant changes in the concentration for each ganglioside. Although ganglioside GT1a/LD1 was not detected in the normal cats, GT1a/LD1 was present in the SD cat. In addition, GQ1b concentration was significantly reduced in the SD cat compared to the normal cat. The concentration of all major gangliosides (GM1, GD1a, GD1b, GT1b, and GQ1b) was reduced in the SD patient compared to the normal human, and these results are consistent with previous findings [21, 22] . In our analysis, we also observed an elevation in GD3 and GT1a/LD1 in the SD human.
While GA2 was undetectable in the normal brains, GA2 accumulated in the SD brains (Table 3 ). Since GA2 is derived from GM2 through the action of a sialidase, we N the number of independent samples analyzed The asterisks indicate that the value is significantly different from the normal strain at ** P \ 0.01 as determined by the two-tailed t test looked at the ratio of GA2-GM2 (lmol/100 mg dry weight) (Fig. 2) . The ratio of GA2-GM2 was 0.93, 0.13, and 0.27 in the SD mice, cats, and humans, respectively. Interestingly, the ratio of GA2-GM2 was greatest in the SD mouse while this ratio was significantly less in the SD cat and human.
Neutral Lipids
The qualitative and quantitative distribution of the neutral brain lipids in mice, cats, and humans with Sandhoff disease (SD) is shown in Fig. 3 and Table 4 . The concentration of cerebrosides, (the myelin-enriched glycolipid), was significantly lower in the SD brains compared to the age-matched control brains. These findings are consistent with previous reports of lower cerebrosides in SD mice and humans [11, 21] . Although statistically significant, the reduction in cerebrosides in the SD mice was less pronounced than in the SD cats and humans. No statistical differences were found between the normal and SD brains for the concentration of cholesterol, ceramide, phosphatidylethanolamine, and phosphatidylcholine. Since sphingomyelin co-migrated with GA2 in our HPTLC solvent system, we did not quantify the concentration of sphingomyelin in the SD brains.
Acidic Lipids
The qualitative and quantitative distribution of the acidic lipids in mice, cats, and human with Sandhoff disease (SD) ND not detectable The asterisks indicate that the value is significantly different from the normal strain at* P \ 0.05 and at ** P \ 0.01 as determined by the twotailed t test a Percent distribution determined from densitometric scanning of HPTLC as shown in Fig. 1 b Concentration expressed as lg sialic acid/100 mg dry weight Lipids (2009) 44:197-205 201 is shown in Fig. 4 and Table 4 . The most noticeable difference in the acidic lipid distribution was the reduction in sulfatides, another myelin-enriched glycolipid, in the SD compared to normal. As with cerebrosides, the SD cat represented an intermediate between the SD mice and the SD humans in terms of the reduction of sulfatides. The presence of some GM2 on the HPTLC plate in the SD samples resulted from lower phase carryover during isolation. No significant differences were observed between the normal and the SD groups for the distribution or content of cardiolipin, phosphatidylserine, and phosphatidylinositol. We further analyzed cerebrosides and sulfatides in SD as a percent of normal (Fig. 5) . The myelin lipids were present at trace levels in the SD humans compared to the normal humans, and the concentration of cerebrosides and sulfatides in the SD mouse was about 58 and 76%, respectively, of that in the normal mouse. Interestingly, the concentration of cerebrosides and sulfatides in the SD cat was about 11 and 14%, respectively, of that in the normal cat. Thus, the lipid profile in the SD cat brain is intermediate to the SD mice and the SD humans in terms of GM2 and GA2 storage, as well as the reduction in cerebrosides and sulfatides.
Discussion
Our results show for the first time the comparative analysis of brain lipids in mice, cats, and humans with SD. In contrast to a previous study, which showed that GM2 was about 42% of the total brain ganglioside distribution in the SD cat, we show that GM2 accounts for 67% of the total ganglioside distribution in the SD cat [19] . The ganglioside distribution in the SD cat in the previous study was analyzed at an earlier age (11 weeks), which could account for CE cholesterol esters, TG triglycerides, IS internal standard, Chol cholesterol, CM ceramide, CB cerebroside (doublet, indicated by arrow), PE phosphatidylethanolamine, PC phosphatidylcholine, SM sphingomyelin, GA2 asialo GM2, LPC lyso-phosphatidylcholine the lower GM2 distribution [19] . For our study, we analyzed the total brain ganglioside distribution at a similar time-point in disease progression in the SD mouse, cat, and human, and we showed that GM2 accumulation in the SD cat is intermediate between the SD mouse and the SD patient. In addition, we also observed an increase in GD3 in the SD human, suggesting an increase in reactive gliosis, perhaps as a result of disease progression [33) . The degree of GM2 accumulation in the SD patient compared to the SD mouse poses a major hurdle in developing therapy, and our results suggest that the SD cat is an appropriate intermediate model to study. In addition to GM2, GA2 was also a major storage material in the SD brain of all the species [2, 11, 12, 20, 21] . The role of GA2 in disease progression is unclear. It is interesting to note, however, that GA2 is unlikely the primary cause of pathogenesis and neurodegeneration in GM2 gangliosidosis, since GA2 accumulation in Tay-Sachs disease is much less than in SD [2, 21] . Also, pathology in GM1 and GM2 retina was associated more with ganglioside accumulation than with accumulation of asialogangliosides [44] . The ratio of GA2-GM2 storage was greater in the SD mouse than in the SD cat or patient. Previous studies showed that sialidase activity is more active in SD mice than in humans and is able to convert significant amounts of GM2 to GA2 [20, [34] [35] [36] . Our results suggest that the activity of the feline sialidase is more similar to the human sialidase than to the mouse sialidase. In addition to abnormal GSL storage, pathogenesis in lysosomal storage diseases is also associated with dysmyelination [21, [37] [38] [39] . Reductions in the myelin-enriched lipids, cerebrosides and sulfatides were shown in the SD mice and in patients with GM2 gangliosidoses [11, 21, 40] . Magnetic resonance imaging analysis also revealed significant white matter changes in the brains of patients and in animal models of GSL storage disorders [37-39, 41, 42] . Furthermore, low angle X-ray diffraction analysis showed hypomyelination in the optic nerves of SD mice [43] . These findings together suggest that the abnormal accumulation of GSLs may influence myelin and that dysmyelination may also contribute to disease progression. Our results showed that the myelin-enriched lipids, cerebrosides and sulfatides are significantly reduced in SD compared to normal. We also found that cerebrosides and sulfatides were significantly reduced in the SD cat compared to the normal cat. Like GM2 accumulation, the reductions in the myelin-enriched lipids in the SD cat were intermediate to that observed in the SD mouse and human.
It is interesting to note that disease onset and eventual death in the SD cats also occur intermediate to these milestones in the SD mice and patients. The SD mice begin to display phenotypic abnormalities at around 12 weeks of age and are humanely euthanized at 16 weeks of age [11, 20] . The onset of disease in the SD mice occurs after sexual maturation, and as a result, the SD mice are able to reproduce [11] . However, behavioral dysfunction is first detected in the SD cats at 6-8 weeks of age and in the SD patient at around 24 weeks of age [2, 19] . The SD cat and patient both succumb to the disease prior to reproduction. Our results show that GM2 storage is greater in SD humans and cats than in SD mice, but that GA2 storage is relatively greater in SD mice than in SD humans and cats. As much of the current progress has been limited to studies in mice, our results suggest that feline SD could be an important model to test and develop potential therapies for patients and could help translate the therapeutic success seen in mice to treatment in humans. 
